EUVIMEDObjevte EUVIMED
BeobachtungsstudieOpen access

Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation

Byeong Geun Song iD, Myeongcheol Lee, Danbee Kang, Wonseok Kang, Ju Hyun Shim, Dong Hyun Sinn iD, Geum-Youn Gwak iD

Alimentary Pharmacology & Therapeutics · 2026-10 · 64 (7) · 940-950

DOI: 10.1111/apt.70807 ↗

At a glance

Beobachtungsstudie in Alimentary Pharmacology & Therapeutics, published online on 2026-06-22. Written by Byeong Geun Song and 6 co-authors. Institution: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Major MEDLINE topics: Adrenergic beta-Antagonists, Liver Cirrhosis. Cited 1 times so far (Crossref); 38 references. The full text is freely available in PubMed Central. Funded by: Korea National Institute of Health.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and Aims Non‐selective beta blockers (NSBBs) are well established for the prevention of variceal bleeding; however, their potential roles beyond this indication remain a matter of debate. We investigated the clinical outcomes of beta‐blocker use in patients with cirrhosis after hospitalisation for cirrhotic complications, excluding variceal bleeding.

Methods

Using the Korean National Health Insurance Service database, we conducted an emulated target trial among 7725 patients with viral hepatitis‐related cirrhosis hospitalised for hepatic encephalopathy, hepatorenal syndrome, ascites, and/or spontaneous bacterial peritonitis (2013–2023), comparing beta‐blocker users ( n = 2455) and non‐users ( n = 5270). The primary outcome was all‐cause death within 6 months; the secondary outcome was rehospitalisation within 3 months.

Results

Compared to beta‐blocker non‐users, those receiving beta‐blocker therapy had a lower risk of all‐cause death within 6 months [cumulative incidence of mortality 7.8% in beta‐blocker users vs. 11.0% in non‐users; adjusted hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.68–0.97]. A lower risk of all‐cause death associated with beta‐blocker use was observed across complication types and patient subgroups. When analysed by dose and agent, each compared with non‐use, an association with lower mortality was observed for low‐dose beta blockers (HR 0.75, 95% CI 0.59–0.94) and for carvedilol (HR 0.55, 95% CI 0.32–0.94), whereas associations for moderate‐to‐high‐dose therapy (HR 0.90, 95% CI 0.71–1.15) and propranolol (HR 0.87, 95% CI 0.72–1.04) were not statistically significant.

Conclusions

Non‐selective beta blockers were associated with reduced mortality and a modest reduction in all‐cause readmission among patients with viral hepatitis‐related cirrhosis after non‐bleeding decompensating events ( ClinicalTrials.gov : NCT06977685).

Subjects

MeSH terms (MEDLINE)

Adrenergic beta-AntagonistsLiver CirrhosisAdultAgedFemaleHumansMaleMiddle AgedHospitalizationRepublic of KoreaTreatment Outcome

Author keywords

cirrhosisdecompensationnon‐selective beta‐blockertarget trial emulation

Substances

Adrenergic beta-Antagonists

Authors and institutions

  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.
  • Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
  • Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

ORCID profiles: Byeong Geun Song, Dong Hyun Sinn, Geum-Youn Gwak

Funding

  • Korea National Institute of Health

Cite

APA

Song, B. G., Lee, M., Kang, D., Kang, W., Shim, J. H., Sinn, D. H., & Gwak, G. Y. (2026). Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation. Alimentary Pharmacology & Therapeutics, 64(7), 940-950. https://doi.org/10.1111/apt.70807

Vancouver

Song BG, Lee M, Kang D, Kang W, Shim JH, Sinn DH, et al. Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation. Alimentary Pharmacology & Therapeutics. 2026;64(7):940-950. doi:10.1111/apt.70807

BibTeX
@article{Song2026,
  author = {Song, Byeong Geun and Lee, Myeongcheol and Kang, Danbee and Kang, Wonseok and Shim, Ju Hyun and Sinn, Dong Hyun and Gwak, Geum-Youn},
  title = {Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {7},
  pages = {940--950},
  doi = {10.1111/apt.70807}
}
Start for free →